Investigational drug · Phase 3
Ziresovir
Also called: AK0529
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Respiratory Syncytial Virus Infections, Respiratory Synctial Virus Infections.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
12
Any phase or sponsor naming "Ziresovir"
First trial start
2024
Feb 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ziresovir", any sponsor or status.
Conditions studied
As listed on its trial records.
- Respiratory Syncytial Virus Infections
- Respiratory Synctial Virus Infections
Approved drugs for the same conditions: RSV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Ziresovir" as an intervention, largest first.
- A Study of AK0529 in Chinese Infants Hospitalized With RSVPivotal-lookingCompleted
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT04231968 · 311 participants · Start Sep 22, 2020 · Primary completion Jan 21, 2022
Drug: AK0529; Matching placebo of AK0529 · For: Respiratory Syncytial Virus Infections
Sites: Beijing, China; Changchun, China; Changsha, China · 28 sites in all
- A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.Pivotal-lookingRecruiting
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT07658534 · 290 participants (planned) · Start Mar 3, 2026 · Primary completion Dec 2028
Drug: Ziresovir (AK0529); Placebo · For: Respiratory Syncytial Virus Infections
Sites: Beijing, China; Guangzhou, China; Cangzhou, China · 9 sites in all
- A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized InfantsPivotal-lookingCompleted
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT06775405 · 180 participants · Start Feb 29, 2024 · Primary completion Apr 7, 2025
Drug: AK0529; Placebo · For: Respiratory Synctial Virus Infections
Sites: Beijing, China; Changchun, China; Changsha, China · 17 sites in all
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT02297594 · 74 participants · Start Oct 2014 · Primary completion Jun 2015
Drug: AK0529; Placebo · For: Respiratory Syncytial Virus Infections
Sites: Brisbane, Australia
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT02654171 · 72 participants · Start May 27, 2016 · Primary completion Mar 31, 2019
Drug: AK0529; Placebo · For: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Sites: Gold Coast, Australia; South Brisbane, Australia; Adelaide, Australia · 28 sites in all
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT03322800 · 51 participants · Start Oct 23, 2017 · Primary completion Apr 6, 2018
Drug: AK0529 · For: Healthy
Sites: Shanghai, China
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT06591845 · 34 participants · Start Sep 25, 2024 · Primary completion Dec 16, 2024
Drug: Ziresovir 125 mg; Ziresovir 500 mg and 2 more · For: Healthy Volunteers
Sites: Glendale, California
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT06942299 · 25 participants · Start Jul 20, 2023 · Primary completion Jun 28, 2024
Drug: AK0529; AK0529 and 1 more · For: Respiratory Syncytial Virus Infections
Sites: Hefei, China; Huangshan City, China; Beijing, China · 42 sites in all
- A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy SubjectsCompleted
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT04788017 · 24 participants · Start Mar 24, 2021 · Primary completion Jun 14, 2021
Drug: Ziresovir · For: Healthy Subjects
Sites: Secaucus, New Jersey
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT03400995 · 7 participants · Start Jan 5, 2018 · Primary completion Feb 27, 2018
Drug: AK0529 · For: Healthy
Sites: Nottingham, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Punicalin targets RSV glycoprotein and fusion protein at non-overlapping sites to prevent viral escape.
Xiong Y, Ming J, Zhang Z, et al. · Cell Rep Med 2026
- Broad-spectrum coronavirus inhibition by RSV fusion inhibitors targeting six-helix bundle formation.
Chen W, Ji MC, Jung E, et al. · Life Sci 2026
- Respiratory syncytial virus (RSV) antibody and small-molecule drugs: current status of clinical translation and challenges.
Liu H, Zhong H, Liu H · Front Microbiol 2026
- Respiratory syncytial virus in high-risk adults: A critical appraisal of therapeutic options and unmet needs.
Mariolis I, Ranellou K, Panagiotopoulos AP, et al. · Respir Med 2026
- Molecular mechanism of ziresovir targeting the fusion glycoprotein of respiratory syncytial virus.
Yan M, Zou J, Gao Z, et al. · PLoS Pathog 2026
- Synthetic oxetanes in drug discovery: where are we in 2025?
Ishikura H, Bull JA · Expert Opin Drug Discov 2025
Also in development for Respiratory Syncytial Virus Infections
- RSVPreF3 OA investigational vaccinePhase 33 trials
GSK · Respiratory Syncytial Virus Infections
- RSVPreF3 OA vaccinePhase 32 trials
GSK · Respiratory Syncytial Virus Infections
- TNM001Phase 32 trials
Zhuhai Trinomab Pharmaceutical Co., Ltd. · Respiratory Syncytial Virus Infections
- Adjuvanted RSVPreF3 vaccinePhase 22 trials
GSK · Cardiovascular Disease, Respiratory Syncytial Virus Infections
- BLB-201PIV5-vectored RSV VaccinePhase 21 trial
Blue Lake Biotechnology Inc. · Respiratory Syncytial Virus Infections
- SYH2066Phase 21 trial
CSPC Ouyi Pharmaceutical Co., Ltd. · Respiratory Syncytial Virus Infections
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.